Solid Biosciences Reports $56.7 Million Net Loss in Q1 2026, Driven by Increased R&D Expenses

Solid Biosciences Inc. reported a net loss of $56.7 million for the first quarter of 2026, an increase of 44.4% compared to a net loss of $39.3 million in the same period of 2025. The company's total operating expenses rose to $57.3 million, up from $40.1 million year-over-year, driven primarily by a 49.3% increase in research and development expenses, which reached $46.1 million. This increase was largely attributed to higher costs associated with the clinical development of SGT-003, a gene therapy candidate for Duchenne muscular dystrophy, as well as increased personnel-related expenses.

In terms of financial position, Solid Biosciences reported total assets of $422.9 million as of March 31, 2026, a significant increase from $232.5 million at the end of 2025. The company’s cash and cash equivalents surged to $297.1 million, up from $59.9 million, following successful capital raises, including a private placement in March 2026 that generated approximately $226.3 million in net proceeds. The company’s accumulated deficit also grew to $1.0 billion, reflecting ongoing investment in its research and development pipeline.

Operationally, Solid Biosciences is advancing several clinical trials, including the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, which has dosed 47 participants as of May 2026. The company has also initiated the IMPACT DUCHENNE Phase 3 trial and the FALCON Phase 1b trial for SGT-212, with initial data expected by the end of 2026. The company’s workforce has expanded, with a notable increase in personnel costs contributing to the rise in general and administrative expenses, which totaled $11.2 million for the quarter.

Looking ahead, Solid Biosciences anticipates continued operating losses as it invests in the development of its gene therapy candidates. The company expects its cash reserves will be sufficient to fund operations into the first half of 2028, although it may need to secure additional funding to support ongoing and future clinical trials. The company remains focused on advancing its pipeline and achieving regulatory approvals for its candidates, which could eventually lead to commercial product revenue.